


Stephen B. Maebius

Partner

smaebius@foley.com

Washington, D.C.
202.672.5569



Drawing upon over 30 years of experience, Stephen (Steve) Maebius helps clients protect their innovations and transact business involving intellectual property assets.

Steve is a partner with Foley & Lardner LLP and leads teams handling a variety of IP work, including IP due diligence reviews, opinions, patent portfolio creation and management, licensing, *inter partes* proceedings involving patents and litigation, and pharmaceutical patent term extensions. He is a former member of the firm's Management Committee and past chair of the IP Practice. Prior to becoming a lawyer, he was a patent examiner in the Biotechnology Group of the U.S. Patent and Trademark Office, gaining experience examining small molecule drugs as well as biologics.

Representative Experience

- Advised Transcend Therapeutics, Inc. on its patent portfolio and assisted with IP due diligence leading up to the company's successful 2026 sale to Otsuka Pharmaceutical Co., Ltd. with a total potential consideration of \$1.225 billion.
- Acted as lead U.S. intellectual property counsel for UK-based Verona Pharma, a biopharmaceutical company focused on respiratory diseases, in its approximately US\$10bn acquisition by Merck & Co. Inc.
- Assisted biotech client with building patent portfolio and presenting IP strategy to VC investors during fundraising, followed by successful IPO.
- Co-counsel in the successful defense of a post-grant review filed against a CRISPR Cpf1 patent (PGR2018-00072).
- Lead counsel in the successful defense of six *inter partes* reviews filed by generic petitioners against a family of Orange Book-listed pharmaceutical patents covering a US\$1bn controlled release product with parallel Hatch-Waxman litigation (IPR2013-00368, IPR2013-00371, and IPR2013-00372 — all claims found patentable in final written decision; IPR2015-01777, IPR2015-01778, and IPR2015-01782 — not instituted).

- Prosecuted a portfolio of product-by-process patents listed in the Orange Book and upheld as valid in subsequent litigation.
- *Takeda Pharmaceutical Co. Ltd. v. John Doll* (Fed. Cir. 2009) – Co-counsel in a precedential 2-1 decision remanding a double patenting rejection arising from patent reexamination (all claims confirmed to be patentable upon remand).
- Licensing of a biotechnology drug with an up-front payment of US\$100m — represented the acquiring company in IP diligence and drafting transaction agreements.

Awards and Recognition

- *IAM Patent 1000 – The World's Leading Patent Practitioners*
 - Post-Grant Patent Procedures (2012-2013, 2020)
 - Prosecution and Transactions (2014-2016, 2020-2021, 2024-present)
- *Chambers Global Intellectual Property – USA and Japan* (2012-2015)
- *Chambers USA for the District of Columbia – Intellectual Property and Patent Prosecution* (2012-2014)
- *Washington, D.C. Super Lawyers® – Intellectual Property* (2014-2020, 2022-2023)
- *The Legal 500*
 - Patent Licensing and Patent Prosecution (2010-2013)
 - Patent Licensing and Transactional (2014 and 2015)
 - Intellectual Property – Patent Prosecution – Utility and Design Patents (2015 and 2016)
 - Healthcare – Life Sciences (2015 and 2016)
- The Best Lawyers in America®
 - Biotechnology and Life Sciences (2007-2026)
 - Litigation – Patent (2012-2026)
 - Patent Law (2012-2024)
 - Intellectual Property (2007-2010)
- *Washingtonian's Best Lawyers in Washington for Intellectual Property* (2013-2014)
- Peer review rated as AV Preeminent®, the highest performance rating in the Martindale-Hubbell® Peer Review Ratings™ system
- *Managing Intellectual Property – IP Star* (2015)
- Two IP transactions in which Steve participated received Licensing Executives Society's "Deal of Distinction"

Presentations and Publications

- Co-author, "Next-Generation Bioprinted Products: Products of Nature or Patentable Innovation?" *IEEE Pulse* (March 28, 2023)
- Co-author, "PTAB's Motion to Amend Pilot Program: Review of Initial Results," *PTAB Trial Insights Blog* (Aug. 19, 2020)
- Co-author, "PTAB – 2019 Year in Review," *PTAB Trial Insights Blog* (Jan. 23, 2020)

- Author, “District Court Sheds Light on Scope of IPR Estoppel,” *PTAB Trial Insights Blog* (Sept. 12, 2019)
- Author, “Revamped PTAB Trial Practice Guide Holds Surprises,” *PTAB Trial Insights Blog* (Aug. 13, 2018)

Thought Leadership

- Principal author, *Due Diligence for Intellectual Property: Valuing Assets in a Transaction*, published by Law Journal Press
- Visiting associate professor of intellectual property law, Tokyo University’s Research Center for Advanced Science and Technology
- Faculty adjunct professor of comparative and international patent law, George Washington University Law School Testified about post-grant patent proceedings during the FTC/DOJ hearings on the “Implications of Competition and Patent Law and Policy,” which preceded the landmark patent legislation known as the America Invents Act
- Co-founder, NanoBusiness Commercialization Association
- Co-founder and associate editor, *Nanotechnology Law & Business Journal*

Sectors

- [Health Care & Life Sciences](#)
- [Pharmaceuticals](#)

Practice Areas

- [Business Method & Software Patents](#)
- [Chemical, Biotechnology & Pharmaceutical](#)
- [China](#)
- [Government Solutions](#)
- [IP Asset Management](#)
- [IP Due Diligence](#)
- [Intellectual Property](#)
- [Japan](#)
- [PTAB Trials](#)
- [Transactions](#)
- [Venture & Growth Capital](#)

Education

- The George Washington University Law School (J.D., 1994)
- Cornell University (B.S., 1989)
 - Biology

Admissions

- District of Columbia
- Virginia
- U.S. Court of Appeals for the Federal Circuit
- U.S. Supreme Court
- U.S. Patent and Trademark Office